Given the relatively small effect estimates in this cognitively healthy population, such an approach likely warrants a combination of plasma NfL with markers of neurodegeneration that capture other parts of the broad spectrum of pathology that underlies the dementia phenotype, notably plasma amyloid-b42 and phosphorylated tau [3, 4]. The gene discussed is MAPT; the disease is dementia.